Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (IRIX) plans to release third-quarter 2026 financial results after the close of trading on November 17, 2026. Management will also provide a business update and host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. A live and recorded webcast will be available through the Event Calendar page in the Investors section at www.iridex.com.
Iridex (IRIX) announced publication of a two-year study evaluating MicroPulse laser therapy in patients with early, moderate and advanced glaucoma. The retrospective study, published in the International Journal of Ophthalmology, evaluated 84 eyes of 53 patients with primary open-angle or primary angle-closure glaucoma.
At 24 months, mean intraocular pressure decreased from 22.32 to 14.05 mmHg, and mean topical pressure-lowering medication use fell from 2.96 to 2.38. Treatment success rates were 86% for open-angle glaucoma and 81% for angle-closure glaucoma. No complications or reductions in visual acuity were reported, and visual field measurements remained stable. All patients previously taking oral acetazolamide discontinued it, with none restarting during follow-up.
Iridex (IRIX) has completed the relocation of its manufacturing facility from Mountain View to San Jose, California. The company expects approximately $0.6 million in annualized cost savings, consistent with its previous expectations, and anticipates further savings opportunities as the transition is fully integrated into operations.
Iridex (Nasdaq: IRIX) reported second quarter 2026 revenue of $12.6 million, down 7% from $13.6 million a year earlier, as weaker retina product sales offset glaucoma growth. Retina revenue declined to $6.5 million from $8.0 million, while Cyclo G6® product family revenue increased 19% to $3.9 million, driven by 17,700 probe sales versus 13,100 in the prior year period.
Gross margin was 34.2%, slightly below 34.5% last year. Operating expenses fell 5% to $5.3 million, reflecting lower general and administrative costs. Net loss widened to $1.3 million, or $0.07 per share, from $1.0 million. Adjusted EBITDA showed a loss of $0.4 million versus a slight profit previously. According to Iridex, operating cash flow was positive, and cash and equivalents were $4.7 million at quarter-end. The company reaffirmed full-year 2026 revenue guidance of $51–$53 million and expects adjusted operating expenses of $19–$19.5 million, while advancing cost reductions through contract manufacturing and relocation to a lower-cost headquarters.
Iridex (Nasdaq: IRIX) will release its second quarter 2026 financial results and provide a business update after the market close on August 18, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, with phone and webcast access available.
Iridex (Nasdaq: IRIX) expanded its partnership with ophthalmology-focused group purchasing organization EyeProGPO by adding Iridex’s EndoProbe® Handpieces to the EyeProGPO product offering. More than 4,300 EyeProGPO members now gain access to preferred pricing on these single-use vitreoretinal laser delivery devices.
The addition complements Iridex’s existing EyeProGPO portfolio, which already includes PASCAL®, IQ 532®, IQ 577®, OcuLight® TX, Cyclo G6® laser consoles and MicroPulse P3®, G-Probe®, and G-Probe Illuminate® devices. According to Iridex, the expanded agreement is intended to broaden member access to its retina laser systems and support ophthalmic providers with a wider range of EndoProbe models and gauges.
Iridex (Nasdaq: IRIX) will present at the Planet MicroCap Las Vegas 2026 Conference. Management is scheduled to present on Wednesday, June 17, 2026 at 4:00 pm PT.
A live and archived webcast will be available via the Event Calendar in the Investors section of the company website.
Iridex (Nasdaq: IRIX) reported Q1 2026 revenue of $11.8 million, down 1% year-over-year. Cyclo G6 product revenue rose 14% to $3.6 million, while retina revenue declined to $5.8 million. Gross margin was 40%, operating expenses fell 4% to $5.1 million, and net loss narrowed to $0.5 million ($0.03 per share).
Non-GAAP adjusted EBITDA was $0.3 million. Cash was $4.6 million, down $1.4 million, with usage concentrated in Q1. Iridex reaffirmed 2026 revenue guidance of $51–$53 million, expects 2026 adjusted operating expenses of $19–$19.5 million, and projects positive operating cash flow for fiscal 2026.
Iridex (Nasdaq: IRIX) will release first-quarter 2026 financial results and provide a business update after market close on May 19, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access via the company website.
Investors can join by phone using Conference ID 9329659 or listen on the Events page at www.iridex.com.
Iridex (Nasdaq: IRIX) announced a partnership with EyeProGPO on April 7, 2026 to provide preferred pricing and expanded access to Iridex retina lasers for more than 1,800 EyeProGPO members.
The agreement adds PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX to EyeProGPO offerings and builds on existing Cyclo G6® and glaucoma probe contracts, aiming to streamline purchasing and broaden clinical access for ophthalmology practices, ASCs, and hospitals.